Baidu
map

PLoS One:阿哌沙班对5种癌症细胞系的体外影响分析

2017-10-23 AlexYang MedSci原创

癌症与血凝过快相关。然而,一些数据表明抗凝药物也许对由血凝依赖的过程和非血凝依赖的过程调控的肿瘤发展和恶化具有影响。因此,有研究人员针对阿哌沙班在5中不同的癌症细胞系中体外的影响,调查了细胞增殖、细胞死亡、细胞迁移、基因表达和基质金属蛋白酶的情况。研究包括了以下的几种癌症细胞系和2中正常成纤维细胞(肺部纤维细胞和皮肤纤维细胞):OVCAR3(卵巢癌)、MDA MB 231(乳腺癌)、CaCO-2(

癌症与血凝过快相关。然而,一些数据表明抗凝药物也许对由血凝依赖的过程和非血凝依赖的过程调控的肿瘤发展和恶化具有影响。因此,有研究人员针对阿哌沙班在5中不同的癌症细胞系中体外的影响,调查了细胞增殖、细胞死亡、细胞迁移、基因表达和基质金属蛋白酶的情况。

研究包括了以下的几种癌症细胞系和2中正常成纤维细胞(肺部纤维细胞和皮肤纤维细胞):OVCAR3(卵巢癌)、MDA MB 231(乳腺癌)、CaCO-2(结肠癌)、LNCap(前列腺癌)和U937(组织细胞性淋巴瘤)。研究人员评估了对照细胞和阿哌沙班处理培养细胞的增殖和细胞死亡情况(剂量从0.1-5微克/毫升,0-96小时)。同时,研究人员评估了坏死/凋亡(荧光显微镜)、细胞迁移(过敏性测试24小时后)、基质金属蛋白酶(MMP)活性和p16、p21和p53以及HAS的mRNA表达(RT PCR)情况。

研究发现,高剂量(5微克/毫升)阿哌沙班处理与3种癌症细胞系(OVCAR3、CaCO-2和 LNCaP)增殖的减少显著相关,并且在除了LACaP癌症细胞系的所有其他细胞系中,细胞的死亡均增加。另外,细胞凋亡与增加的细胞死亡有关。迁移能力在阿哌沙班处理的OVCAR3和CaCO-2细胞中减弱。mRNA表达数据表明了在所有细胞系中,肿瘤抑制基因p16的表达均增加。最后,研究人员指出,他们的数据表明了高剂量的阿哌沙班能够在体外试验中干扰到癌症细胞系,并且在一些癌症细胞系中,可减少癌症细胞增殖和通过细胞凋亡增加癌症细胞死亡。

原始出处:

Guasti L, Squizzato A, Moretto P et al. In vitro effects of Apixaban on 5 different cancer cell lines. PLoS One. 12 Oct 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933133, encodeId=72581933133d8, content=<a href='/topic/show?id=489ee1465be' target=_blank style='color:#2F92EE;'>#癌症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71465, encryptionId=489ee1465be, topicName=癌症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Apr 11 19:45:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790053, encodeId=68e81e90053dc, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 08 17:45:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554013, encodeId=68aa15540132f, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Wed Oct 25 12:45:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255448, encodeId=440a2554487c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Oct 23 22:00:43 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255437, encodeId=5fef25543ec1, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:09 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2018-04-11 zhwj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933133, encodeId=72581933133d8, content=<a href='/topic/show?id=489ee1465be' target=_blank style='color:#2F92EE;'>#癌症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71465, encryptionId=489ee1465be, topicName=癌症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Apr 11 19:45:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790053, encodeId=68e81e90053dc, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 08 17:45:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554013, encodeId=68aa15540132f, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Wed Oct 25 12:45:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255448, encodeId=440a2554487c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Oct 23 22:00:43 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255437, encodeId=5fef25543ec1, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:09 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933133, encodeId=72581933133d8, content=<a href='/topic/show?id=489ee1465be' target=_blank style='color:#2F92EE;'>#癌症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71465, encryptionId=489ee1465be, topicName=癌症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Apr 11 19:45:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790053, encodeId=68e81e90053dc, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 08 17:45:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554013, encodeId=68aa15540132f, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Wed Oct 25 12:45:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255448, encodeId=440a2554487c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Oct 23 22:00:43 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255437, encodeId=5fef25543ec1, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:09 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1933133, encodeId=72581933133d8, content=<a href='/topic/show?id=489ee1465be' target=_blank style='color:#2F92EE;'>#癌症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71465, encryptionId=489ee1465be, topicName=癌症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Apr 11 19:45:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790053, encodeId=68e81e90053dc, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 08 17:45:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554013, encodeId=68aa15540132f, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Wed Oct 25 12:45:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255448, encodeId=440a2554487c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Oct 23 22:00:43 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255437, encodeId=5fef25543ec1, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:09 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 清风拂面

    谢谢分享.学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1933133, encodeId=72581933133d8, content=<a href='/topic/show?id=489ee1465be' target=_blank style='color:#2F92EE;'>#癌症细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71465, encryptionId=489ee1465be, topicName=癌症细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Wed Apr 11 19:45:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790053, encodeId=68e81e90053dc, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 08 17:45:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554013, encodeId=68aa15540132f, content=<a href='/topic/show?id=7482e7994d0' target=_blank style='color:#2F92EE;'>#细胞系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77994, encryptionId=7482e7994d0, topicName=细胞系)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c9f14484011, createdName=zhangxingru, createdTime=Wed Oct 25 12:45:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255448, encodeId=440a2554487c, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Oct 23 22:00:43 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255437, encodeId=5fef25543ec1, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Oct 23 21:48:09 CST 2017, time=2017-10-23, status=1, ipAttribution=)]
    2017-10-23 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

JAHA:阿哌沙班、达比加群,利伐沙班预防房颤患者卒中发生的有效性和安全型

背景:非维生素K拮抗剂这种口服抗凝剂是房颤患者卒中预防的一大进步;然而,临床试验中取得的成果不能转化到日常实践中。研究者通过与华法林对比,旨在评估利伐沙班、达比加群和阿哌沙班的有效性和安全性。方法和结果:使用美国大型保险数据库,研究者确定私人保险和医疗保险中,2010年10月1日和2015年6月30日期间,应用阿哌沙班、达比加群,利伐沙班,或华法林的非瓣膜性房颤患者。研究者采用1:1的倾向得分匹配

BMJ:多药疗法背景下阿哌沙班与华法林治疗房颤的疗效比较(ARISTOTLE)

研究者对ARISTOTLE(2006-2011年,多中心、双盲、双模拟试验,阿哌沙班可减少房颤患者卒中和其他血栓栓塞事件风险)研究结果进行了事后分析,涉及18201名参与者,探究越来越多的伴随药物背景下,阿哌沙班和华法林对房颤治疗的差异。ARISTOTLE试验中患者被随机分为每天2次5 mg阿哌沙班组(n=9120)或华法林组(以国际标准化比值范围2.0-3.0为目标;n = 9081)。事后分析

Ann Pharmacother:避免肾功能损伤 快用阿哌沙班替代华法林吧!

2017年4月,发表在《Pharmacotherapy》的一项由美国科学家组织的研究,调查了严重肾功能损伤患者中,阿哌沙班替代华法林的理由。研究目的:仅基于一项将肌酐清除率(CrCl)<25ml/分或血清肌酐浓度(SCr)>2.5mg/dl的患者排除在外的阿哌沙班临床试验的药物代谢动力学数据,美国食品和药物管理局批准阿哌沙班用于(CrCl)<15ml/分或透析治疗的患者。因此,本研究的目的为评估阿

Blood:用凝血酶原复合物管理利伐沙班或阿哌沙班引起的主要出血事件的效果。

用凝血酶原复合物(PCC)管理因利伐沙班或阿哌沙班而引起的主要出血事件(MBE)的有效性以及在患者中血栓栓塞事件的发生率都存在不确定性。Ammar Majeed及其同事对PCC用于管理应用利伐沙班或阿哌沙班引起的MBE的效果进行研究。

预防卒中,哪种新型药物有效?

几十年来,房颤患者预防卒中发生,口服抗凝药是唯一的降血稀释剂。应用华法林需要持续监测其效果,并且华法林受到大量的药物和食物的相互作用。现在一些非维生素K拮抗剂口服抗凝药物(NOAC)可用于房颤患者。在一项发表于CHEST杂志的研究表明,梅奥诊所的心脏病专家Peter Noseworthy,和他的同事比较了三种NOACs(达比加群,利伐沙班和阿哌沙班)有效性和安全性。Noseworthy说:“大型随

2015 NICE技术评估指南:阿哌沙班用于深静脉血栓形成和/或肺栓塞的治疗和二级预防(TA341)

2015年6月,英国国家卫生与临床优化研究所 (NICE)发布了阿哌沙班用于深静脉血栓形成和/或肺栓塞的治疗和二级预防的技术评估指南。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载) 

Baidu
map
Baidu
map
Baidu
map